CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

Rhea-AI Summary

CytoDyn (OTCQB: CYDY), a clinical-stage oncology company, will present research findings on its lead drug leronlimab at the AACR Special Conference on Cancer Immunity from September 24-27, 2025, in Montreal. The company's Lead Consultant, Dr. Richard Pestell, will deliver both poster and oral presentations focusing on leronlimab's effects on metastatic triple-negative breast cancer (TNBC).

The research suggests that leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, may convert 'cold' tumors to 'hot' tumors, potentially enhancing responsiveness to checkpoint inhibitors. This mechanism could have broad implications for treating solid tumors with limited treatment options.

News Market Reaction – CYDY

+7.14%

1 alert

+7.14% News Effect

On the day this news was published, CYDY gained 7.14%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced it has been selected for a poster and an oral presentation at the upcoming AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, taking place September 24 to 27, 2025, in Montreal, Canada.

Richard Pestell, M.D., Ph.D., FRCP, AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will deliver a podium presentation on the effects of leronlimab on metastatic triple-negative breast cancer.

“We are encouraged by these findings, which suggest that leronlimab may convert ‘cold’ tumors into ‘hot’ ones, making them more responsive to checkpoint inhibitors in diseases like metastatic triple-negative breast cancer, an aggressive disease with substantial unmet need,” said Dr. Pestell, “The results of this research will also help to shed light on an underlying mechanism of action for leronlimab with potential broad applicability for solid tumors with limited treatment options.”

Details of the oral and poster presentations are as follows:

Abstract Title:
CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long‑term survival in metastatic TNBC

Presenter:
Richard Pestell, M.D., Ph.D., FRCP AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn

Poster presentation:
September 26, 2025, 6:30 p.m. – 8:30 p.m. EDT

Podium/speaking presentation:
September 27, 2025, 10:25 a.m. – 10:40 a.m. EDT

About CytoDyn
CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.  

For more information, please visit www.cytodyn.com and follow us on LinkedIn.

Note Regarding Forward-Looking Statements

This news release may contain forward-looking statements relating to, among other things, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law. 

Corporate Contact

CytoDyn Inc.
ir@cytodyn.com

Media Contacts
Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com

FAQ

When will CytoDyn present at the AACR Special Conference 2025?

CytoDyn will present a poster on September 26, 2025 at 6:30-8:30 p.m. EDT and give an oral presentation on September 27, 2025 at 10:25-10:40 a.m. EDT.

What is CytoDyn's leronlimab drug designed to treat?

Leronlimab is being developed for multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC). It's a first-in-class humanized monoclonal antibody targeting the CCR5 receptor.

Who will present CytoDyn's research at the AACR conference?

Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will deliver the presentations.

What are the key findings of CytoDyn's leronlimab research?

The research suggests that leronlimab may convert 'cold' tumors into 'hot' ones, potentially making them more responsive to checkpoint inhibitors in diseases like metastatic triple-negative breast cancer.